Although IMM might contribute to an increased cancer risk (despite their control of the underlying chronic inflammation), available data remain inconsistent.
Cross-sectional and longitudinal analysis of the Swiss IBD cohort elucidated prevalence and incidence of cancer next to protective and risk factors, including the role of IMM. Data on IBD patients included between 2007 and 2013 were initially analysed in a cross-sectional manner. Patients with malignancies (=composite of cancer, dysplasia and lymphoma) were compared with controls.
A total of 122 malignancy cases (3.9%) were detected in a total number of 3,119 patients. Most patients had gastrointestinal carcinoma (23.0%), dysplasia (22.1%), or skin cancer (9.0%). Patients with malignancies were more often male, older at the age of diagnosis, and had longer IBD duration. Fistula, intestinal surgery, and surgery for fistula were more frequently reported. Cancer patients were more often found to...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Long-term safety profile of adalimumab Next Article
Cobitolimod induces anti-inflammatory effects by balancing Th17/T-reg cell response »